share_log

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

欧库根被费城评为2022年最佳工作场所之一
GlobeNewswire ·  2022/06/14 19:05

MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the "2022 Best Places to Work."

宾夕法尼亚州马尔文,2022年6月14日(环球网)--致力于发现、开发新型基因和细胞疗法、生物制剂和疫苗并将其商业化的生物技术公司欧库根公司(纳斯达克代码:OCGN)今天宣布,该公司被《费城商业日报》评为“2022年最佳工作场所”之一。

"This recognition validates our efforts to build a great corporate culture, since employees are the ones surveyed for this honor," said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc. "We see this as an opportunity to highlight the great work we're doing to improve health and bring innovative treatments to patients. Our people are the most important part of fulfilling that mission."

Ocugen公司董事长、首席执行官兼联合创始人Shankar Musunuri博士说:“这一认可证实了我们建立伟大企业文化的努力,因为员工是这一荣誉的调查对象。”我们认为这是一个机会,可以突显我们在改善健康和为患者带来创新治疗方面所做的伟大工作。我们的员工是完成这一使命的最重要的部分。

The Philadelphia Business Journal partnered with Quantum Workplace to identify Greater Philadelphia's Best Places to Work. This year's list includes 76 companies from across the region, ranked by employee feedback. Nominated by the public, employees from each company were surveyed and the results were evaluated before creating the list.
Quantum Workplace's survey measures each company's culture and takes into consideration compensation, benefits and trust in senior leadership across five different categories based on business size. Ocugen is grouped in the Greater Philadelphia area's medium-sized businesses (50-99 employees). Winners of each category will be named on July 28 at an awards ceremony in Philadelphia.

《费城商业日报》与Quantum Workplace合作,评选出大费城最佳工作场所。今年的榜单包括来自亚洲各地的76家公司,按员工反馈排名。由公众提名,每个公司的员工都接受了调查,并在创建榜单之前对结果进行了评估。
Quantum Workplace的调查衡量了每家公司的文化,并根据企业规模考虑了五个不同类别的薪酬、福利和对高级领导层的信任。欧库根集团位于大费城地区的中型企业(50-99名员工)中。每个奖项的获奖者将于7月28日在费城举行的颁奖仪式上揭晓。

Career opportunities at Ocugen can be found on the Company's website:

欧库根的职业机会可以在该公司的网站上找到:

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at and follow us on Twitter and LinkedIn.

欧库根公司简介.
Ocugen,Inc.是一家生物技术公司,专注于发现、开发和商业化新的基因和细胞疗法、生物制品和疫苗,这些疗法可以改善健康,为人们和全球社区带来希望。我们正在通过大胆的创新产生影响,将科学带入为患者服务的新方向。我们突破性的修饰剂基因治疗平台具有用一种药物治疗多种疾病的潜力,我们正在推进其他治疗领域的研究,为没有得到满足的医疗需求的人提供新的选择。在Twitter和LinkedIn上了解更多并关注我们。

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

关于前瞻性陈述的警示说明
本新闻稿包含1995年《私人证券诉讼改革法》所指的前瞻性陈述,这些陈述会受到风险和不确定性的影响。在某些情况下,我们可能会使用“预测”、“相信”、“潜在”、“建议”、“继续”、“估计”、“预期”、“预期”、“计划”、“打算”、“可能”、“将”、“应该”或其他表达未来事件或结果不确定性的词语来识别这些前瞻性陈述。此类陈述会受到许多重要因素、风险和不确定因素的影响,这些因素、风险和不确定因素可能会导致实际事件或结果与我们目前的预期大不相同。这些以及其他风险和不确定性在我们提交给美国证券交易委员会(“美国证券交易委员会”)的定期报告中有更全面的描述,包括我们在提交给美国证券交易委员会的季度和年度报告中题为“风险因素”的章节中描述的风险因素。我们在本新闻稿中所作的任何前瞻性陈述仅限于本新闻稿发布之日。除非法律另有要求,否则我们没有义务在本新闻稿发布之日之后,因新信息、未来事件或其他原因而更新本新闻稿中包含的前瞻性陈述。

Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent / Daniel Kontoh-Boateng (Investor)
jnugent@tiberend.com
dboateng@tiberend.com

联系人
Tiberend战略顾问公司
Jonathan Nugent/Daniel Kontoh-Boateng(投资者)
邮箱:jnugent@tiberend.com
邮箱:dboateng@tiberend.com

Dave Schemelia (Media)
dschemelia@tiberend.com

戴夫·斯皮利亚(Dave Schemelia)(媒体)
邮箱:dschemelia@tiberend.com


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发